Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for Agitation in Dementia (MAGD)
NCT00371059Phase 4Completed
- Sponsor
- East Kent Hospitals
- Start
- Sep 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Alzheimer's disease (AD) comparing Memantine with Placebo (2 arms). Primary endpoint: Cohen-Mansfield Agitation Inventory at 12 weeks. Started Sep 2007; status: completed.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00371059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00371059.